FILE - This April 28, 2010, file photo shows the GlaxoSmithKline offices in London. On Friday, July 20, 2018, the U.S. Food and Drug Administration approved GlaxoSmithKline’s Krintafel, a simpler, one-dose treatment, to prevent relapses of malaria. (AP Photo/Kirsty Wigglesworth, File)

Simpler, one-dose treatment to prevent malaria relapse OK'd

July 20, 2018 - 5:58 pm

U.S. regulators have approved a simpler, one-dose treatment to prevent relapses of malaria.

Standard treatment takes two weeks and many patients don't finish taking all the doses.

Malaria is caused by parasites that are spread through mosquito bites. The parasites can remain dormant in the liver and cause relapses months or years later.

The new drug targets the parasite that is behind most of the infections in South America and Asia. The vast majority of malaria cases and deaths are in Africa, and they involve another species.

In testing, one dose of the new drug worked about the same as the standard two-week treatment.

GlaxoSmithKline says the Food and Drug Administration approved Krintafel (KRIN'-tah-fell) on Friday.

Malaria causes flu-like symptoms and sometimes is fatal, mostly in young children.

AP Editorial Categories: